SI-BONE Inc. (SIBN) Tops Q4 EPS by 1c, Beats on Revenue; Offers FY24 Revenue Guidance

Go back to SI-BONE Inc. (SIBN) Tops Q4 EPS by 1c, Beats on Revenue; Offers FY24 Revenue Guidance

SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance

February 26, 2024 4:09 PM EST

SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Fourth Quarter 2023 Highlights (all comparisons are to the prior year period)

Worldwide revenue of $38.9 million, representing an increase of ~22%U.S. revenue of $36.7 million, representing an increase of ~22%Gross Margin of ~74%, reflecting a ~4 percentage point reduction from excess inventory reserveOver 1,130 active physicians, representing... More